Juan Ortiz-Álvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Ortiz-Álvarez has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- José-Juan Pereyra-Rodríguez
Department of Medicine, University of Seville, Seville, Spain
6 shared publications - Juan-Carlos Hernández-Rodríguez
Department of Dermatology, Virgen del Rocio University Hospital, Seville, Spain
5 shared publications - Julián Conejo-Mir
Dermatology Department Hospital Universitario Virgen del Rocío Sevilla Spain
5 shared publications Julián Conejo-Mir Sánchez
Hospital Universitario Virgen del Rocío
4 shared publicationsJuan Carlos Hernández-Rodríguez
Department of Dermatology, Virgen del Rocio University Hospital, Seville, Spain
3 shared publications- Mercedes Sendín-Martín
Department of Dermatology Virgen del Rocio University Hospital Seville Spain
3 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (9) , 104671
Adalimumab-related Spondylodiscitis: A Side Effect to be Taken into Consideration
- 15 May 2026
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (9) , 104671
Open AccessAdalimumab-related Spondylodiscitis: A Side Effect to be Taken into Consideration
- Open Access
- 11 December 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (3) , 104538
Hospitalizations Due to Hidradenitis Suppurativa in Spain Between 2016 and 2021: Demographic and Stratified Analysis by Sex for a Population Cohort
- 11 December 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (3) , 104538
Open AccessHospitalizations Due to Hidradenitis Suppurativa in Spain Between 2016 and 2021: Demographic and Stratified Analysis by Sex for a Population Cohort
- 4 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (3) , 685-687
Skin Health for All: Improving Dermatological Care for Migrants and Underserved Populations in Malta and Greece
- 4 December 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (3) , 685-687
Skin Health for All: Improving Dermatological Care for Migrants and Underserved Populations in Malta and Greece
- 10 April 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (3) , 254-259
Brodalumab for moderate–severe hidradenitis suppurativa: An open‐label multicentric cohort study in real clinical practice
Introduction: The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF‐alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL‐17, thus having a promising role in the treatment of HS.Material and methods: A multicenter retrospective observational open‐label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow‐up time. Demographic and disease‐related variables as well as response parameters (HiSCR and IHS4) and safety data were recorded and analysed.Results: A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in three patients with no fatal outcomes and treatment discontinuation was advised in four patients.Conclusions: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.
- 10 April 2024
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 65 (3) , 254-259
Brodalumab for moderate–severe hidradenitis suppurativa: An open‐label multicentric cohort study in real clinical practice
Introduction: The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF‐alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL‐17, thus having a promising role in the treatment of HS.Material and methods: A multicenter retrospective observational open‐label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at weeks 0 and 16 which was the median follow‐up time. Demographic and disease‐related variables as well as response parameters (HiSCR and IHS4) and safety data were recorded and analysed.Results: A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in three patients with no fatal outcomes and treatment discontinuation was advised in four patients.Conclusions: Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only widely approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.
- Open Access
- 11 March 2024
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 115 (5) , T475-T492
[Translated article] Spanish Academy of Dermatology and Venereology (AEDV) expert recommendations for the management of sexual transmitted parasitosis. Scabies, and pediculosis pubis
- 11 March 2024
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 115 (5) , T475-T492
Open Access[Translated article] Spanish Academy of Dermatology and Venereology (AEDV) expert recommendations for the management of sexual transmitted parasitosis. Scabies, and pediculosis pubis
- Open Access
- 5 December 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 115 (5) , 475-492
Recomendaciones de expertos de la Academia Española de Dermatología (AEDV) para el manejo de las ectoparasitosis de transmisión sexual. Escabiosis y pediculosis púbica
- 5 December 2023
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 115 (5) , 475-492
Open AccessRecomendaciones de expertos de la Academia Española de Dermatología (AEDV) para el manejo de las ectoparasitosis de transmisión sexual. Escabiosis y pediculosis púbica
- 23 October 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (6) , 1081-1085
Genetic and dermoscopic findings in a case series of children with oculocutaneous albinism
Oculocutaneous albinism (OCA) is a genetic disease caused by disorders in melanin synthesis or distribution. In this descriptive study conducted in a tertiary care pediatric hospital, patients with a clinical diagnosis of OCA and genetic study were retrospectively recruited and underwent dermatological and ophthalmological exam, including optical coherence tomography (OCT) and digital dermoscopy. Our findings revealed milder OCA phenotypic expression in individuals harboring single pathogenic mutations in conjunction with polymorphisms, as well as in those with mutations of uncertain significance. Regardless OCA subgroup, severe phenotypes of OCA were associated with a higher number of mutations/polymorphisms in melanin biosynthesis genes and paler dermoscopic patterns, such as vascular pattern, which was the most common pattern in our series.
- 23 October 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (6) , 1081-1085
Genetic and dermoscopic findings in a case series of children with oculocutaneous albinism
Oculocutaneous albinism (OCA) is a genetic disease caused by disorders in melanin synthesis or distribution. In this descriptive study conducted in a tertiary care pediatric hospital, patients with a clinical diagnosis of OCA and genetic study were retrospectively recruited and underwent dermatological and ophthalmological exam, including optical coherence tomography (OCT) and digital dermoscopy. Our findings revealed milder OCA phenotypic expression in individuals harboring single pathogenic mutations in conjunction with polymorphisms, as well as in those with mutations of uncertain significance. Regardless OCA subgroup, severe phenotypes of OCA were associated with a higher number of mutations/polymorphisms in melanin biosynthesis genes and paler dermoscopic patterns, such as vascular pattern, which was the most common pattern in our series.
- Open Access
- 9 May 2023
- Published by Springer Nature in Research Square
Brodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practice
Introduction The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS. Material and methods A multicenter longitudinal observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at week 0 and week 16. Demographic and disease-related variables as well as response parameters (HiSCR, IHS4 and PGA) and safety were recorded and analyzed. Results A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in 3 patients with no fatal outcomes and treatment discontinuation was advised in 4 patients. Conclusions Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.
- 9 May 2023
- Published by Springer Nature in Research Square
Open AccessBrodalumab for moderate-severe hidradenitis suppurativa: an open-label multicentric cohort study in real clinical practice
Introduction The use of biological therapy is becoming increasingly common in patients with hidradenitis suppurativa (HS). Levels of serum TNF-alfa and IL17 support the role of an immune system dysregulation in the pathogenesis of HS. Brodalumab targets the receptor A of IL-17, thus having a promising role in the treatment of HS. Material and methods A multicenter longitudinal observational open-label study was conducted in two tertiary hospitals. Adults with moderate to severe HS under treatment with brodalumab 210 mg at week 0, 1, 2 and then every 2 weeks were included and assessed at week 0 and week 16. Demographic and disease-related variables as well as response parameters (HiSCR, IHS4 and PGA) and safety were recorded and analyzed. Results A total of 16 patients (75% males) were included in our study. 50% of patients presented an inflammatory phenotype and mean BMI was 28.37. HiSCR was achieved in 50% of patients and mean IHS4 decreased from 24.13 to 16.81 (p = 0.002). No differences were found between those who achieved HiSCR and those who did not. Grade 2 adverse events were reported in 3 patients with no fatal outcomes and treatment discontinuation was advised in 4 patients. Conclusions Brodalumab seems to be effective and safe in patients with moderate to severe HS, even in those that did not respond to adalimumab, which, at the moment, is the only approved biologic for this indication. Thus, it stands as an interesting option for the treatment of HS.
- Open Access
- 27 March 2023
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (7) , 752-758
Prediction of melanoma Breslow thickness using deep transfer learning algorithms
Background: The distinction between in situ melanoma (MIS) and invasive melanoma is challenging even for expert dermatologists. The use of pretrained convolutional neural networks (CNNs) as ancillary decision systems needs further research. Aim: To develop, validate and compare three deep transfer learning (DTL) algorithms to predict MIS vs. invasive melanoma and melanoma with a Breslow thickness (BT) of < 0.8 mm vs. ≥ 0.8 mm. Methods: A dataset of 1315 dermoscopic images of histopathologically confirmed melanomas was created from Virgen del Rocio University Hospital and open repositories of the International Skin Imaging Collaboration archive and Polesie S et al. (Dermatol Pract Concept 2021; 11:e2021079). The images were labelled as MIS or invasive melanoma and < 0.8 mm or ≥ 0.8 mm of BT. We conducted three trainings, and overall means for receiver operating characteristic (ROC) curves, sensitivity, specificity, positive and negative predictive value, and balanced diagnostic accuracy outcomes were evaluated on the test set with ResNetV2, EfficientNetB6 and InceptionV3. The results of 10 dermatologists were compared with the algorithms. Grad-CAM gradient maps were generated, highlighting relevant areas considered by the CNNs within the images. Results: EfficientNetB6 achieved the highest diagnostic accuracy for the comparison between MIS vs. invasive melanoma (61%) and BT < 0.8 mm vs. ≥ 0.8 mm (75%). For the BT comparison, ResNetV2 with an area under the ROC curve of 0.76 and InceptionV3 with an area under the ROC curve of 0.75, outperformed the results obtained by the dermatologist group with an area under the ROC curve of 0.70. Conclusion: EfficientNetB6 recorded the best prediction results, outperforming the dermatologists for the comparison of 0.8 mm of BT. DTL could be an ancillary aid to support dermatologists’ decisions in the near future.
- 27 March 2023
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 48 (7) , 752-758
Open AccessPrediction of melanoma Breslow thickness using deep transfer learning algorithms
Background: The distinction between in situ melanoma (MIS) and invasive melanoma is challenging even for expert dermatologists. The use of pretrained convolutional neural networks (CNNs) as ancillary decision systems needs further research. Aim: To develop, validate and compare three deep transfer learning (DTL) algorithms to predict MIS vs. invasive melanoma and melanoma with a Breslow thickness (BT) of < 0.8 mm vs. ≥ 0.8 mm. Methods: A dataset of 1315 dermoscopic images of histopathologically confirmed melanomas was created from Virgen del Rocio University Hospital and open repositories of the International Skin Imaging Collaboration archive and Polesie S et al. (Dermatol Pract Concept 2021; 11:e2021079). The images were labelled as MIS or invasive melanoma and < 0.8 mm or ≥ 0.8 mm of BT. We conducted three trainings, and overall means for receiver operating characteristic (ROC) curves, sensitivity, specificity, positive and negative predictive value, and balanced diagnostic accuracy outcomes were evaluated on the test set with ResNetV2, EfficientNetB6 and InceptionV3. The results of 10 dermatologists were compared with the algorithms. Grad-CAM gradient maps were generated, highlighting relevant areas considered by the CNNs within the images. Results: EfficientNetB6 achieved the highest diagnostic accuracy for the comparison between MIS vs. invasive melanoma (61%) and BT < 0.8 mm vs. ≥ 0.8 mm (75%). For the BT comparison, ResNetV2 with an area under the ROC curve of 0.76 and InceptionV3 with an area under the ROC curve of 0.75, outperformed the results obtained by the dermatologist group with an area under the ROC curve of 0.70. Conclusion: EfficientNetB6 recorded the best prediction results, outperforming the dermatologists for the comparison of 0.8 mm of BT. DTL could be an ancillary aid to support dermatologists’ decisions in the near future.
- Open Access
- 20 February 2023
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (6) , 776-782
Skin cancer mortality in Spain: adjusted mortality rates by province and related risk factors
Background: Ultraviolet radiation is the main environmental risk factor responsible for the development of skin cancer. Other occupational, socioeconomic, and environmental factors appear to be related to the risk of skin cancer. Furthermore, the factors appear to differ for melanoma and non‐melanoma skin cancer (NMSC). The purpose of this study is to analyze mortality rates of skin cancer in the different provinces of Spain and to determine the influence of socioeconomic conditions and other environmental and demographic factors in rates.Methods: Deaths from melanoma and NMSC in the period 2000–2019 were obtained as well as socioeconomic and environmental variables. Annual standardized mortality rates (SMR) were calculated for all Spanish provinces. The Pearson correlation coefficient was calculated.Results: The SMR of melanoma was 2.10/100,000 inhabitants, while that of NMSC was 1.28/100,000. At the provincial level, a great variability is confirmed. Gross domestic product showed a positive correlation with melanoma mortality but a negative correlation with NMSC. Other environmental and socioeconomic variables also showed correlation, as a positive correlation between tobacco sales and melanoma and between agricultural development and the NMSC.Conclusions: There are still important differences between each province that must be taken into account when planning health care and resource distribution. This ecological and province‐wise study helps to elucidate the relationship between social and ambient exposure determinants and skin cancer mortality in Spain.
- 20 February 2023
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (6) , 776-782
Open AccessSkin cancer mortality in Spain: adjusted mortality rates by province and related risk factors
Background: Ultraviolet radiation is the main environmental risk factor responsible for the development of skin cancer. Other occupational, socioeconomic, and environmental factors appear to be related to the risk of skin cancer. Furthermore, the factors appear to differ for melanoma and non‐melanoma skin cancer (NMSC). The purpose of this study is to analyze mortality rates of skin cancer in the different provinces of Spain and to determine the influence of socioeconomic conditions and other environmental and demographic factors in rates.Methods: Deaths from melanoma and NMSC in the period 2000–2019 were obtained as well as socioeconomic and environmental variables. Annual standardized mortality rates (SMR) were calculated for all Spanish provinces. The Pearson correlation coefficient was calculated.Results: The SMR of melanoma was 2.10/100,000 inhabitants, while that of NMSC was 1.28/100,000. At the provincial level, a great variability is confirmed. Gross domestic product showed a positive correlation with melanoma mortality but a negative correlation with NMSC. Other environmental and socioeconomic variables also showed correlation, as a positive correlation between tobacco sales and melanoma and between agricultural development and the NMSC.Conclusions: There are still important differences between each province that must be taken into account when planning health care and resource distribution. This ecological and province‐wise study helps to elucidate the relationship between social and ambient exposure determinants and skin cancer mortality in Spain.